Meet the MedCity Media Team

And take 2 minutes to help us make better for you.

Every year, we ask you to tell us a little about yourself (anonymously) to help us create better, more relevant content and features for you. We consider every response and very much appreciate you taking the time to assist us.

Please click the button above to open a simple, multiple choice survey that should only take 2 minutes to complete.

Thank you,

The MedCity Media Team

FDA warns Stryker on quality issues, marketing practices

9:06 am by | 0 Comments

(Reuters) - Orthopedic implant maker Stryker Corp said it received a warning letter from the U.S. Food and Drug Administration related to quality concerns at its Portage, Michigan facility.

The letter also said Stryker failed to notify the regulator of a product recall, and had been marketing devices without approval.

The FDA acknowledged that Stryker has submitted corrective action plans for the quality and recall issues, Stryker said.

Stryker shares were down about 0.5 percent at $65.90 in premarket trading.

(Reporting by Esha Dey in Bangalore; Editing by Joyjeet Das)

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Hear the latest news first

Get our daily newsletter or follow us.